CTLA4 and neoplasm: These monoclonal antibodies, blocking immune checkpoint-relevant molecules such as PD1, PD-L1, and CTLA-4, exert their effect by inhibiting the immunosuppressive signals in T cells, thus amplifying T cell-mediated tumor cytotoxicity.